Vaccitech Shares Resume Trade
Save time and jump to the most important pieces.
4 - Barinthus Biotherapeutics plc. (0001828185) (Issuer)
4 - Barinthus Biotherapeutics plc. (0001828185) (Issuer)
4 - Barinthus Biotherapeutics plc. (0001828185) (Issuer)
New Corporate Brand to be Unveiled at AASLD Liver Meeting® 2023 with Interim Data
Gainers Plus Therapeutics (NASDAQ:PSTV) shares rose 20.3% to $1.48 during Tuesday's after-market session. Today's trading volume for this security ended up closing at 1.0 million shares, which is 236.3 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $4.2 million. The company's, Q3 earnings came out today. NewAmsterdam Pharma (NASDAQ:NAMS) shares increased by 11.11% to $10.0. The company's market cap stands at $823.2 million. China SXT Pharmaceuticals (NASDAQ:SXTC) shares increased by 10.23% to $2.37. The company's market cap stands at $1.3 million. DarioHealth (NASDAQ:DRIO) stock moved upwards by 7.81% to $1.38. The market value of
Gainers Soleno Therapeutics (NASDAQ:SLNO) shares increased by 426.2% to $23.31 during Tuesday's regular session. Soleno Therapeutics's stock is trading at a volume of 32.5 million shares as of 13:30 EST. This is 51215.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $232.9 million. Femasys (NASDAQ:FEMY) shares rose 272.43% to $1.24. As of 13:30 EST, Femasys's stock is trading at a volume of 147.8 million, which is 3882.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $18.6 million. DMK Pharmaceuticals (NASDAQ:DMK) stock rose 160.42% to $1.18. Trading volume for this secu
OXFORD, United Kingdom, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel T cell immunotherapeutics designed to harness the power of the immune system to treat chronic infectious diseases, cancer and autoimmunity, today announced its financial results for the second quarter of 2023 and provided an overview of the Company's progress. "In the second quarter of 2023, Vaccitech achieved important clinical milestones for two of our lead programs in HPV and HBV, which included the final analysis for the Phase 1b/2a trial of VTP-300 presented at EASL," said Bill Enright, Vaccitech's Ch
OXFORD, United Kingdom, May 12, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity and cancer, today announced its financial results for the first quarter of 2023 and an overview of the Company's progress. "2023 has kicked off strongly for Vaccitech. In the first quarter, we strengthened our leadership team with the addition of Dr. Nadège Pelletier as our new Chief Scientific Officer, we generated positive final proof of concept data from one of o
OXFORD, United Kingdom, March 24, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity and cancer, today announced its financial results for year end 2022 and an overview of the Company's progress. "2022 represented an extremely active year at Vaccitech in which the company continued to advance its exciting pipeline and strengthen the infrastructure necessary to support this and future growth. We announced the completion of enrollment of three clinical trials, and initiate
SC 13G/A - Barinthus Biotherapeutics plc. (0001828185) (Subject)
SC 13G/A - Vaccitech plc (0001828185) (Subject)
SC 13G - Vaccitech plc (0001828185) (Subject)
8-K - Barinthus Biotherapeutics plc. (0001828185) (Filer)
8-K - Barinthus Biotherapeutics plc. (0001828185) (Filer)
8-K - Barinthus Biotherapeutics plc. (0001828185) (Filer)
New Corporate Brand to be Unveiled at AASLD Liver Meeting® 2023 with Interim Data OXFORD, United Kingdom, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS), formerly Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer will present data from its Phase 2 Hepatitis B trials of VTP-300 at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023, November 10-14 in Boston, MA. The company also announced today that it has changed its name to Barinthus Biotherapeu
OXFORD, United Kingdom, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel T cell immunotherapeutics designed to harness the power of the immune system to treat chronic infectious diseases, cancer and autoimmunity, today announced it will host a Key Opinion Leader (KOL) Webinar to discuss the current treatment landscape for people living with chronic Hepatitis B Virus (HBV) infection and potential paths to a functional cure. Details are as follows: KOL Webinar: Seeking a Functional Cure for Chronic Hepatis BWednesday, September 20, 2023 between 14:00-15:00 ET.To register for the event
OXFORD, United Kingdom, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel T cell immunotherapeutics designed to harness the power of the immune system to treat chronic infectious diseases, cancer and autoimmunity, today announced its financial results for the second quarter of 2023 and provided an overview of the Company's progress. "In the second quarter of 2023, Vaccitech achieved important clinical milestones for two of our lead programs in HPV and HBV, which included the final analysis for the Phase 1b/2a trial of VTP-300 presented at EASL," said Bill Enright, Vaccitech's Ch